CRON:CA:TSX-Cronos Group Inc.

EQUITY | Drug Manufacturers | Toronto Stock Exchange

Last Closing

CAD 27.47

Change

-0.82 (-2.90)%

Market Cap

CAD 9.03B

Volume

1.40M

Analyst Target

CAD 14.86
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2019-03-21 )

Largest Industry Peers for Drug Manufacturers

ETFs Containing CRON:CA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers) Market Performance vs. Exchange (Toronto Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 91.03% 82% B 99% N/A
Dividend Return N/A N/A N/A N/A F
Total Return 91.03% 82% B 99% N/A
Trailing 12 Months  
Capital Gain 166.70% 100% F 100% F
Dividend Return N/A N/A N/A N/A F
Total Return 166.70% 100% F 100% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A F
Dividend Return N/A N/A N/A N/A F
Total Return N/A N/A N/A N/A F
Average Annual (5 Year Horizon)  
Capital Gain 4.30% 50% F 69% C-
Dividend Return 4.30% 50% F 56% F
Total Return N/A N/A N/A N/A F
Risk Return Profile  
Volatility (Standard Deviation) 24.82% 60% D- 29% F
Risk Adjusted Return 17.33% 60% D- 37% F
Market Capitalization 9.03B 82% B 97% N/A

Key Financial Ratios

  Ratio vs. Industry/Classification (Drug Manufacturers) Ratio vs. Market (Toronto Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio -915.67 100% 100%
Price/Book Ratio 21.63 6% 1%
Price / Cash Flow Ratio -38.15 88% 98%
Price/Free Cash Flow Ratio -34.34 94% 93%
Management Effectiveness  
Return on Equity -3.28% 71% 29%
Return on Invested Capital -6.21% 53% 16%
Return on Assets -3.08% 71% 26%
Debt to Equity Ratio 3.75% 91% 91%

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative earnings

The company had negative total earnings in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.